TBPH logo

TBPH
Theravance Biopharma Inc

1,029
Mkt Cap
$861.99M
Volume
99,740.00
52W High
$21.03
52W Low
$8.33
PE Ratio
8.26
TBPH Fundamentals
Price
$16.69
Prev Close
$16.74
Open
$16.73
50D MA
$16.01
Beta
0.57
Avg. Volume
954,669.35
EPS (Annual)
$2.06
P/B
2.88
Rev/Employee
$1.19M
$723.84
Loading...
Loading...
News
all
press releases
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·14h ago
News Placeholder
More News
News Placeholder
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are covering the stock, MarketBeat Ratings...
MarketBeat·6d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving Average - Here's What Happened
Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Below Two Hundred Day Moving Average - Time to Sell...
MarketBeat·8d ago
News Placeholder
Theravance Stock Declines Around 17% in Three Months: Here's Why
TBPH shares sink in three months after its lead drug fails a late-stage study, forcing a pipeline overhaul and raising uncertainty over its future direction.
Zacks·15d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·15d ago
News Placeholder
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·16d ago
News Placeholder
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates
TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI & KORSINSKY, LLP Investigates TBPH: Reported $22M in Operating Expenses While Advancing Trial Enrollment -- LEVI...
PR Newswire·16d ago
News Placeholder
Tudor Investment Corp ET AL Sells 145,515 Shares of Theravance Biopharma, Inc. $TBPH
Tudor Investment Corp ET AL cut its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 74.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 51,048 shares of the biopharmaceutical...
MarketBeat·16d ago
News Placeholder
Zacks Research Has Positive Estimate for TBPH Q1 Earnings
Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Research analysts at Zacks Research upped their Q1 2026 EPS estimates for shares of Theravance Biopharma in a research note issued to investors on Thursday, April 9th. Zacks Research analyst Team now anticipates that the biopharmaceutical comp...
MarketBeat·17d ago
News Placeholder
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised Theravance Biopharma from a "buy" rating to a "strong-buy" rating in a research note on Tuesday...
MarketBeat·17d ago
<
1
2
...
>

Latest TBPH News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.